Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction

Open access

Abstract

Radiotherapy-induced immune activation holds great promise for optimizing cancer treatment efficacy. Here, we describe a clinically used radiosensitizer hafnium oxide (HfO 2 ) that was core coated with a MnO 2 shell followed by a glucose oxidase (GOx) doping nanoplatform (HfO 2 @MnO 2 @GOx, HMG) to trigger ferroptosis adjuvant effects by glutathione depletion and reactive oxygen species production. This ferroptosis cascade potentiation further sensitized radiotherapy by enhancing DNA damage in 4T1 breast cancer tumor cells. The combination of HMG nanoparticles and radiotherapy effectively activated the damaged DNA and Mn 2+ -mediated cGAS-STING immune pathway in vitro and in vivo. This process had significant inhibitory effects on cancer progression and initiating an anticancer systemic immune response to prevent distant tumor recurrence and achieve long-lasting tumor suppression of both primary and distant tumors. Furthermore, the as-prepared HMG nanoparticles “turned on” spectral computed tomography (CT)/magnetic resonance dual-modality imaging signals, and demonstrated favorable contrast enhancement capabilities activated by under the GSH tumor microenvironment. This result highlighted the potential of nanoparticles as a theranostic nanoplatform for achieving molecular imaging guided tumor radiotherapy sensitization induced by synergistic immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-024-02502-8

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Schematic illustration of the mechanism of HfO2@MnO2@GOx nanoparticles in the combination therapy of breast cancer
Scheme 1 Schematic illustration of the mechanism of HfO2@MnO2@GOx nanoparticles in the combination therapy of breast cancerCC BY · PubMed Central
Fig. 1 (A) The characterization of HfO2@MnO2 (HM) nanoparticles: TEM images and STEM-EDS elemental maps. (B-C) The ROS production ability of HM nanoparticles at different H2O2 concentrations measured by UV spectrophotometry. (B) Spectrograms in the range of 400–800 nm. (C) Comparison of absorption values at 665 nm for each group. (D) Changes in surface charge of nanoparticles during the amide reaction. Indirect reflection of GOx activity by UV spectrophotometric analysis of gluconic acid measurements (E) and by measurement of H2O2 content (F) in each group of solutions. (G) The ROS production ability of HM and HMG nanoparticles by oxidatively fading MB (665 nm) at different GSH concentrations (0, 0.1, 0.5, 1 mM). CT brightness (H) and density values (I) of HMG nanoparticles and iodine agent at different concentrations at 50 keV monoenergetic spectral CT. (J) CT values of HMG nanoparticles and iodine agent with increasing keV at Hf or I concentration of 500 µg/ mL. Magnetic resonance T1-weighted imaging (K) and T1 relaxation rates (L) of different materials (Gd-DTPA, HMG, HMG + GSH) with increasing concentrations of Mn or Gd. (****p < 0.0001)
Fig. 1 (A) The characterization of HfO2@MnO2 (HM) nanoparticles: TEM images and STEM-EDS elemental maps. (B-C) The ROS production ability of HM nanoparticles at different H2O2 concentrations measured by UV spectrophotometry. (B) Spectrograms in the range of 400–800 nm. (C) Comparison of absorption values at 665 nm for each group. (D) Changes in surface charge of nanoparticles during the amide reaction. Indirect reflection of GOx activity by UV spectrophotometric analysis of gluconic acid measurements (E) and by measurement of H2O2 content (F) in each group of solutions. (G) The ROS production ability of HM and HMG nanoparticles by oxidatively fading MB (665 nm) at different GSH concentrations (0, 0.1, 0.5, 1 mM). CT brightness (H) and density values (I) of HMG nanoparticles and iodine agent at different concentrations at 50 keV monoenergetic spectral CT. (J) CT values of HMG nanoparticles and iodine agent with increasing keV at Hf or I concentration of 500 µg/ mL. Magnetic resonance T1-weighted imaging (K) and T1 relaxation rates (L) of different materials (Gd-DTPA, HMG, HMG + GSH) with increasing concentrations of Mn or Gd. (****p < 0.0001)CC BY · PubMed Central
Fig. 2 (A) Schematic diagram of ferroptosis. (B) Cell viability after incubation of 3T3 or 4T1 cells with different nanoparticles (H, HM, and HMG). (C) Intracellular GSH and (D) H2O2 content of 4T1 cells after co-incubation with different nanomaterials. ROS content observed and measured by inverted microscopy (E) and flow cytometry (F) after co-incubation of 4T1 cells with different nanomaterials. Fluorescence images (G) and flow analysis (H) of 4T1 cells treated with different nanoparticles (PBS, H, HM, and HMG) to assess the extent of intracellular lipid peroxidation using C11-BODIPY. The expression of intracellular GPX4 and PTGS2 proteins in 4T1 cells by after treatment with different nanoparticles by western blotting (I) and the relative expression of GPX4 (J) and PTGS2 (K) proteins in different treatment groups. (L) Cell viability after incubation of different groups of 4T1 cells with Fer-1 (ferroptosis inhibitor). (Scale bar = 100 μm; *p < 0.1, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Fig. 2 (A) Schematic diagram of ferroptosis. (B) Cell viability after incubation of 3T3 or 4T1 cells with different nanoparticles (H, HM, and HMG). (C) Intracellular GSH and (D) H2O2 content of 4T1 cells after co-incubation with different nanomaterials. ROS content observed and measured by inverted microscopy (E) and flow cytometry (F) after co-incubation of 4T1 cells with different nanomaterials. Fluorescence images (G) and flow analysis (H) of 4T1 cells treated with different nanoparticles (PBS, H, HM, and HMG) to assess the extent of intracellular lipid peroxidation using C11-BODIPY. The expression of intracellular GPX4 and PTGS2 proteins in 4T1 cells by after treatment with different nanoparticles by western blotting (I) and the relative expression of GPX4 (J) and PTGS2 (K) proteins in different treatment groups. (L) Cell viability after incubation of different groups of 4T1 cells with Fer-1 (ferroptosis inhibitor). (Scale bar = 100 μm; *p < 0.1, ** p < 0.01, *** p < 0.001, **** p < 0.0001)CC BY · PubMed Central
Fig. 3 Optical diagrams (A) and counts (B) of colony formation of 4T1 cells after incubation with PBS or different nanoparticles (H, HM, and HMG) after exposure to different radiation doses (0, 2, 4, 6 Gy). (C) Cell viability of 4T1 cells after different treatments. Fluorescence intensity (D) and confocal fluorescence images (E) of DNA damage in 4T1 cells under different treatments. (F) Expression of cGAS-STING pathway-related proteins in 4T1 cells of different treatment groups. (G-H) The maturation of DC cells under different treatments assessed by flow cytometry. (Scale bar = 50 μm; ***p < 0.001, ****p < 0.0001)
Fig. 3 Optical diagrams (A) and counts (B) of colony formation of 4T1 cells after incubation with PBS or different nanoparticles (H, HM, and HMG) after exposure to different radiation doses (0, 2, 4, 6 Gy). (C) Cell viability of 4T1 cells after different treatments. Fluorescence intensity (D) and confocal fluorescence images (E) of DNA damage in 4T1 cells under different treatments. (F) Expression of cGAS-STING pathway-related proteins in 4T1 cells of different treatment groups. (G-H) The maturation of DC cells under different treatments assessed by flow cytometry. (Scale bar = 50 μm; ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central
Fig. 4 (A) Illustration of the treatment schedule used to assess the impact of intratumorally injected nanoparticles on primary tumors. Body weight (B) and tumor volume (C) changes of mice in each treatment group. (D) Photograph, H&E staining, immunochemical staining (PTGS2, γ-H2AX), and TUNEL staining in tumor-bearing mice after 14 days of treatment. (Scale bar = 200 μm; **p < 0.01)
Fig. 4 (A) Illustration of the treatment schedule used to assess the impact of intratumorally injected nanoparticles on primary tumors. Body weight (B) and tumor volume (C) changes of mice in each treatment group. (D) Photograph, H&E staining, immunochemical staining (PTGS2, γ-H2AX), and TUNEL staining in tumor-bearing mice after 14 days of treatment. (Scale bar = 200 μm; **p < 0.01)CC BY · PubMed Central
Fig. 5 Magnetic resonance T1-weighted images (A) and relative signal-to-noise ratio (B) of mice before and after intravenous injection of saline or HMG nanoparticle solution. (C) Illustration of the treatment schedule used to assess the impact of i.v. injected NPs on primary tumors. (D) Body weight and (E) tumor volume changes in each treatment group. (F) Photograph, H&E staining, immunochemical staining (PTGS2, γ-H2AX), and TUNEL staining in mice after 14 days of treatment. (Scale bar = 200 μm; **p < 0.01, ****p < 0.0001)
Fig. 5 Magnetic resonance T1-weighted images (A) and relative signal-to-noise ratio (B) of mice before and after intravenous injection of saline or HMG nanoparticle solution. (C) Illustration of the treatment schedule used to assess the impact of i.v. injected NPs on primary tumors. (D) Body weight and (E) tumor volume changes in each treatment group. (F) Photograph, H&E staining, immunochemical staining (PTGS2, γ-H2AX), and TUNEL staining in mice after 14 days of treatment. (Scale bar = 200 μm; **p < 0.01, ****p < 0.0001)CC BY · PubMed Central
Fig. 6 Activation of the immune response in vivo. (A) Schematic diagram of immune response in vivo. (B) Schematic illustration showing the animal experiment design. Changes in body weight (C) and volume of contralateral metastatic tumors (D) during treatment. (E) Expression of cGAS-STING pathway-related proteins in tumortissues. (F) Levels of IFN-β in the serum. (G) Maturation of DC cells in the lymph nodes of mice after treatment. (H-I) Proportion of CD4+ and CD8+ T cells in tumor tissues after treatment. (J) Immunofluorescence images of tumor sections for CD8+ T cells stained with CD3 (red), CD8 (green), and nuclear (blue). (K) The quantification of CD4+ FOXP3+ (Treg) in tumor. (L-N) Levels of IFN-β, TNF-α, and IL-6 at tumor sites in mice. (Scale bars: 100 μm, **p < 0.01, ***p < 0.001, ****p < 0.0001)
Fig. 6 Activation of the immune response in vivo. (A) Schematic diagram of immune response in vivo. (B) Schematic illustration showing the animal experiment design. Changes in body weight (C) and volume of contralateral metastatic tumors (D) during treatment. (E) Expression of cGAS-STING pathway-related proteins in tumortissues. (F) Levels of IFN-β in the serum. (G) Maturation of DC cells in the lymph nodes of mice after treatment. (H-I) Proportion of CD4+ and CD8+ T cells in tumor tissues after treatment. (J) Immunofluorescence images of tumor sections for CD8+ T cells stained with CD3 (red), CD8 (green), and nuclear (blue). (K) The quantification of CD4+ FOXP3+ (Treg) in tumor. (L-N) Levels of IFN-β, TNF-α, and IL-6 at tumor sites in mice. (Scale bars: 100 μm, **p < 0.01, ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

33 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 43

Metadata

Authors
Hu, H., Zheng, S., He, C., Zheng, Y., Wei, Q., Chen, S., Wu, Z., Xu, Y., Zhao, B., & Yan, C.
Affiliations
  • Second Affiliated Hospital of Guangzhou Medical University (CN)
  • Nanfang Hospital (CN)
  • Guangdong Provincial Hospital of Chinese Medicine (CN)
  • Southern Medical University (CN)
Corresponding author
  • Xu, Yikai
  • Zhao, Bingxia
  • Yan, Chenggong
Venue
Journal of Nanobiotechnology
Published
2024-05-09
Volume
22
Issue
1
Pages
234-234
ISSN
1477-3155 (ISSN-L)
OpenAlex
W4396765487
Cited by
43
References
39
Citations by year
2026: 20 · 2025: 20 · 2024: 3
FWCI
4.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the National Natural Science Foundation of China (81871334, 82072056, 81801764)
  • Guangdong Basic and Applied Basic Research Foundation (2021A1515011882, 2017A050506011)
  • Medical Scientific Research Foundation of Guangdong Province (A2018014)
  • the Pearl River Talented Young Scholar Program (2017GC010282)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
radiosensitization, cancer immunotherapy, cGAS-STING pathway, hafnium oxide nanoparticles, glucose oxidase, ferroptosis, glutathione depletion, reactive oxygen species, DNA damage, 4T1 breast cancer, theranostic nanoplatform, tumor microenvironment
MeSH terms
Ferroptosis, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Animals, DNA Damage, Female, Glucose Oxidase, Humans, Immunotherapy, Membrane Proteins, Mice, Inbred BALB C, Nucleotidyltransferases, Oxides, Radiation-Sensitizing Agents, Reactive Oxygen Species, Manganese Compounds, Cell Line, Tumor, Mice, Nanoparticles, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction. https://app.cochat.ai/papers/10.1186/s12951-024-02502-8
The paper
Hu, H., Zheng, S., He, C., Zheng, Y., Wei, Q., Chen, S., Wu, Z., Xu, Y., Zhao, B., & Yan, C. (2024). Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-024-02502-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.